Cargando…

Novel pharmacologic approach to enhance the epigenetic and immune priming effect of decitabine in patients with advanced non-small cell lung cancer

Detalles Bibliográficos
Autores principales:	Velcheti, Vamsidhar, Pennell, Nathan A, Rakshit, Sagar, Stevenson, James, Shapiro, Marc, Almeida, Francisco A, Gurajala, Ram, Schalper, Kurt Alex, Saunthararajah, Yogen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645121/ http://dx.doi.org/10.1186/2051-1426-3-S2-P178

Ejemplares similares

Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen
por: Saleh, Mostafa F. M., et al.
Publicado: (2017)

High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects
por: Ebrahem, Quteba, et al.
Publicado: (2012)

Decitabine Suspends Human CD34(+) Cell Differentiation and Proliferation during Lentiviral Transduction
por: Uchida, Naoya, et al.
Publicado: (2014)

Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy
por: Biswas, Sudipta, et al.
Publicado: (2023)

A non‐cytotoxic regimen of decitabine to treat refractory T‐cell large granular lymphocytic leukemia
por: Zawit, Misam, et al.
Publicado: (2021)

Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients
por: Khunger, Monica, et al.
Publicado: (2018)

Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
por: Carvajal-Hausdorf, Daniel E., et al.
Publicado: (2017)

Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion
por: Chilakala, Sujatha, et al.
Publicado: (2019)

Combinatorial targeting of epigenome-modifying enzymes with decitabine and RN-1 synergistically increases HbF
por: Ibanez, Vinzon, et al.
Publicado: (2023)

Prediction of recurrence in early stage non-small cell lung cancer using computer extracted nuclear features from digital H&E images
por: Wang, Xiangxue, et al.
Publicado: (2017)

A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
por: Gore, Lia, et al.
Publicado: (2017)

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)
por: Carvajal-Hausdorf, Daniel, et al.
Publicado: (2019)

Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancer
por: Schalper, Kurt Alex, et al.
Publicado: (2015)

S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis)
por: Lavelle, Donald, et al.
Publicado: (2010)

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors
por: Negrotto, Soledad, et al.
Publicado: (2011)

High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas
por: Velcheti, Vamsidhar, et al.
Publicado: (2013)

Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study
por: Molokie, Robert, et al.
Publicado: (2017)

P524: PHARMACODYNAMICALLY DEFINED METRONOMIC DOSING OF DECITABINE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA
por: Fedorov, Kateryna, et al.
Publicado: (2023)

Targeting sickle cell disease root-cause pathophysiology with small molecules
por: Saunthararajah, Yogen
Publicado: (2019)

Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation
por: Saunthararajah, Yogen
Publicado: (2020)

Extended experience with a non‐cytotoxic DNMT1‐targeting regimen of decitabine to treat myeloid malignancies
por: Awada, Hassan, et al.
Publicado: (2019)

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
por: Wang, Yao, et al.
Publicado: (2021)

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC
por: Lemmon, Christopher A., et al.
Publicado: (2022)

Epigenetic synergy between decitabine and platinum derivatives
por: Qin, Taichun, et al.
Publicado: (2015)

Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network
por: Gu, Xiaorong, et al.
Publicado: (2020)

Decitabine: a historical review of the development of an epigenetic drug
por: de Vos, Dick, et al.
Publicado: (2005)

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
por: Yin, Jia, et al.
Publicado: (2021)

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab
por: Khunger, Monica, et al.
Publicado: (2017)

5613127 PHARMACOKINETICS AND PHARMACODYNAMICS OF AN INNOVATIVE ORAL FORMULATION OF DECITABINE AND TETRAHYDROURIDINE IN HEALTHY PEOPLE
por: Saunthararajah, Y., et al.
Publicado: (2023)

Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells
por: Grunewald, Camilla M., et al.
Publicado: (2021)

Epigenetic Priming with Decitabine Augments the Therapeutic Effect of Cisplatin on Triple-Negative Breast Cancer Cells through Induction of Proapoptotic Factor NOXA
por: Nakajima, Wataru, et al.
Publicado: (2022)

5-aza-2′,2′-Difluroro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of Cancer
por: Daifuku, Richard, et al.
Publicado: (2017)

Management of patients with advanced non-small cell lung cancer: role of gefitinib
por: Velcheti, Vamsidhar, et al.
Publicado: (2010)

Role of immune-checkpoint inhibitors in lung cancer
por: Jain, Prantesh, et al.
Publicado: (2018)

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience
por: Khunger, Arjun, et al.
Publicado: (2018)

Quantitative vessel tortuosity: A potential CT imaging biomarker for distinguishing lung granulomas from adenocarcinomas
por: Alilou, Mehdi, et al.
Publicado: (2018)

Author Correction: Quantitative vessel tortuosity: A potential CT imaging biomarker for distinguishing lung granulomas from adenocarcinomas
por: Alilou, Mehdi, et al.
Publicado: (2019)

Epigenetic Anti‐Cancer Treatment With a Stabilized Carbocyclic Decitabine Analogue
por: Traube, Franziska R., et al.
Publicado: (2022)

Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells
por: Enane, Francis O., et al.
Publicado: (2018)

Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications
por: Halaban, Ruth, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_qt2rbsabq8qbj9aoonlnnuh10f